Troriluzole

Small molecule

Filedunder review

Evidence outlook · regulatory review

Spinocerebellar Ataxia: application under FDA review

FDA accepts the troriluzole (Vyglxia) NDA resubmission for SCA (2026-10-22). A filing is the sponsor's claim that its evidence supports approval; this platform grades the trials, not the filing. The event is listed under Regulatory events.

NCT03701399: Randomized, quadruple-blind and placebo-controlled, but the primary measure (change in f-SARA ataxia score at week 48 in all participants) was not significantly different from placebo (difference -0.06, p=0.7581). A favourable difference in the SCA3 genetic subgroup (p=0.0450) does not change the result of the main comparison.

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (6)
Spinocerebellar Ataxia
Open Pilot Trial of BHV-4157active not recruiting
NCT03408080 · University of California, Los Angeles
2017-12-15 – 2024-12-15 · Spinocerebellar Ataxias, Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2, Spinocerebellar Ataxia 3, Spinocerebellar Ataxia Type 6, MSA-C
What this study did
Other / comorbidity
NCT04708834 · Biohaven Pharmaceuticals, Inc.
2021-03-30 – 2026-02-13 · Obsessive Compulsive Disorder
What this study did
NCT04641143 · Biohaven Pharmaceuticals, Inc.
2020-12-22 – 2025-10-27 · Obsessive-Compulsive Disorder
What this study did
NCT04693351 · Biohaven Pharmaceuticals, Inc.
2021-01-29 – 2025-04-29 · Obsessive-Compulsive Disorder
What this study did
NCT03829241 · Biohaven Pharmaceuticals, Inc.
2019-02-19 – 2020-05-08 · Generalized Anxiety Disorder
What this study did
Phase 2/3 (3)
Spinocerebellar Ataxia
NCT02960893 · Biohaven Pharmaceuticals, Inc.
2016-12-15 – 2024-09-20 · Spinocerebellar Ataxias, Spinocerebellar Ataxia Genotype Type 1, Spinocerebellar Ataxia Genotype Type 2, Spinocerebellar Ataxia Genotype Type 3, Spinocerebellar Ataxia Genotype Type 6, Spinocerebellar Ataxia Genotype Type 7, Spinocerebellar Ataxia Genotype Type 8, Spinocerebellar Ataxia Genotype Type 10
What this study did
Other / comorbidity
NCT03970447 · Global Coalition for Adaptive Research
2019-07-30 – 2030-06 · Glioblastoma
What this study did
NCT03299166 · Biohaven Pharmaceuticals, Inc.
2017-12-19 – 2025-12-08 · Obsessive-Compulsive Disorder
What this study did
Phase 2 (2)
Other / comorbidity
NCT04899921 · Dana-Farber Cancer Institute
2021-06-30 – 2023-05-29 · Melanoma, Metastatic Melanoma
What this study did
NCT03605667 · Biohaven Pharmaceuticals, Inc.
2018-07-31 – 2021-12-23 · Alzheimer Disease
What this study did
Phase 1 (2)
Other / comorbidity
NCT06989853 · William Stoops
2025-08-25 – 2029-02-28 · Methamphetamine Use Disorder
What this study did
NCT06552260 · Ugonma Chukwueke
2025-02-19 – 2027-08-01 · Glioblastoma, Recurrent Glioblastoma, Brain Tumor
What this study did

Competitive landscape

No competitors sharing a mechanism or indication in the current universe.

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Troriluzole to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
June 2028 (1)
Phase 2/3GlioblastomaRecruiting
Est. primary completion 2028-06 · NCT03970447 · CT.gov ↗
What to watch
2029 (1)
February 2029 (1)
Phase 1Methamphetamine Use DisorderRecruiting
Est. primary completion 2029-02-28 · NCT06989853 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(5)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

22 October 2026Filing acceptedFDA accepts the troriluzole (Vyglxia) NDA resubmission for SCA
US, FDA · Biohaven · Source ↗
4 November 2025Complete response letterFDA issues complete response letter for VYGLXIA (troriluzole) NDA in spinocerebellar ataxia
US, FDA · Biohaven · Source ↗
11 February 2025Filing acceptedFDA accepts troriluzole NDA for SCA
US, FDA · Source ↗
11 February 2025Priority reviewFDA grants Priority Review to troriluzole NDA
US, FDA · Source ↗
16 December 2024Filing submittedTroriluzole NDA submitted for SCA
US, FDA · Source ↗